Key facts
- eGlint’s last known valuation is $7.4M (Nov 2021).
- It has raised $2.4M; the latest was Early Stage VC in Jun 2025.
- Notable investors include CONNECT (San Diego), Breakthrough Energy, Ulu Ventures, Wilson Sonsini Goodrich & Rosati, SeedFolio — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for eGlint
- ·The full record, as it builds
Funding rounds
No funding rounds for eGlint are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About eGlint
Developer of a rapid, multiplex, multiomic diagnostics platform intended to transform how biological information is measured and used in clinical care. The company offers thermally responsive, aptamer-based biosensors that generate quantitative signals through target-induced stability shifts, enabling clinicians, researchers, and patients, faster and highly sensitive detection of proteins, small molecules, and other biomarkers.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2021
- Employees
- 5
- Website
- eglint.com/
- Ownership
- Privately Held (backing)
eGlint doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in eGlint shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on eGlint in its N-PORT filings yet. We sweep new filings monthly.